@article{GoebelerBataCsoergőSimoneetal.2022,
  author    = {Goebeler, M. and Bata-Cs{\"o}rgő, Z. and Simone, C. de and Didona, B. and Remenyik, E. and Reznichenko, N. and Stoevesandt, J. and Ward, E. S. and Parys, W. and Haard, H. de and Dupuy, P. and Verheesen, P. and Schmidt, E. and Joly, P.},
  title     = {Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open-label feasibility trial},
  series = {British Journal of Dermatology},
  volume    = {186},
  journal   = {British Journal of Dermatology},
  number    = {3},
  doi       = {10.1111/bjd.20782},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-258328},
  pages     = {429-439},
  year      = {2022},
  abstract  = {Background Pemphigus vulgaris and pemphigus foliaceus are potentially life-threatening autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal desmogleins. There is an unmet need for fast-acting drugs that enable patients to achieve early sustained remission with reduced corticosteroid reliance. Objectives To investigate efgartigimod, an engineered Fc fragment that inhibits the activity of the neonatal Fc receptor, thereby reducing serum IgG levels, for treating pemphigus. Methods Thirty-four patients with mild-to-moderate pemphigus vulgaris or foliaceus were enrolled in an open-label phase II adaptive trial. In sequential cohorts, efgartigimod was dosed at 10 or 25 mg kg\(^{-1}\) intravenously with various dosing frequencies, as monotherapy or as add-on therapy to low-dose oral prednisone. Safety endpoints comprised the primary outcome. The study is registered at ClinicalTrials.gov (identifier NCT03334058). Results Adverse events were mostly mild and were reported by 16 of 19 (84\%) patients receiving efgartigimod 10 mg kg\(^{-1}\) and 13 of 15 (87\%) patients receiving 25 mg kg-1, with similar adverse event profiles between dose groups. A major decrease in serum total IgG and anti-desmoglein autoantibodies was observed and correlated with improved Pemphigus Disease Area Index scores. Efgartigimod, as monotherapy or combined with prednisone, demonstrated early disease control in 28 of 31 (90\%) patients after a median of 17 days. Optimized, prolonged treatment with efgartigimod in combination with a median dose of prednisone 0·26 mg \(^{-1}\) per day (range 0·06-0·48) led to complete clinical remission in 14 of 22 (64\%) patients within 2-41 weeks. Conclusions Efgartigimod was well tolerated and exhibited an early effect on disease activity and outcome parameters, providing support for further evaluation as a therapy for pemphigus.},
  language  = {en}
}
@article{KleijnWinfreeBartomeusetal.2015,
  author    = {Kleijn, David and Winfree, Rachael and Bartomeus, Ignasi and Carvalheiro, Lu{\´i}sa G. and Henry, Mickael and Isaacs, Rufus and Klein, Alexandra-Maria and Kremen, Claire and M'Gonigle, Leithen K. and Rader, Romina and Ricketts, Taylor H. and Williams, Neal M. and Adamson, Nancy Lee and Ascher, John S. and B{\´a}ldi, Andr{\´a}s and Bat{\´a}ry, P{\´e}ter and Benjamin, Faye and Biesmeijer, Jacobus C. and Blitzer, Eleanor J. and Bommarco, Riccardo and Brand, Mariette R. and Bretagnolle, Vincent and Button, Lindsey and Cariveau, Daniel P. and Chifflet, R{\´e}my and Colville, Jonathan F. and Danforth, Bryan N. and Elle, Elizabeth and Garratt, Michael P. D. and Herzog, Felix and Holzschuh, Andrea and Howlett, Brad G. and Jauker, Frank and Jha, Shalene and Knop, Eva and Krewenka, Kristin M. and Le F{\´e}on, Violette and Mandelik, Yael and May, Emily A. and Park, Mia G. and Pisanty, Gideon and Reemer, Menno and Riedinger, Verena and Rollin, Orianne and Rundl{\"o}f, Maj and Sardi{\~n}as, Hillary S. and Scheper, Jeroen and Sciligo, Amber R. and Smith, Henrik G. and Steffan-Dewenter, Ingolf and Thorp, Robbin and Tscharntke, Teja and Verhulst, Jort and Viana, Blandina F. and Vaissi{\`e}re, Bernard E. and Veldtman, Ruan and Ward, Kimiora L. and Westphal, Catrin and Potts, Simon G.},
  title     = {Delivery of crop pollination services is an insufficient argument for wild pollinator conservation},
  series = {Nature Communications},
  volume    = {6},
  journal   = {Nature Communications},
  number    = {7414},
  doi       = {10.1038/ncomms8414},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-151879},
  year      = {2015},
  abstract  = {There is compelling evidence that more diverse ecosystems deliver greater benefits to people, and these ecosystem services have become a key argument for biodiversity conservation. However, it is unclear how much biodiversity is needed to deliver ecosystem services in a cost- effective way. Here we show that, while the contribution of wild bees to crop production is significant, service delivery is restricted to a limited subset of all known bee species. Across crops, years and biogeographical regions, crop-visiting wild bee communities are dominated by a small number of common species, and threatened species are rarely observed on crops. Dominant crop pollinators persist under agricultural expansion and many are easily enhanced by simple conservation measures, suggesting that cost- effective management strategies to promote crop pollination should target a different set of species than management strategies to promote threatened bees. Conserving the biological diversity of bees therefore requires more than just ecosystem-service-based arguments.},
  language  = {en}
}